Pfizer zenarestat
Executive Summary
Phase III development of aldose reductase inhibitor for the treatment of diabetic neuropathy suspended Oct. 13 following reports of potential dose-dependent renal toxicity in "a small number of patients," primarily those on the 1,200 mg/day dose, Pfizer says. Efficacy data support continued development efforts with related compounds, company says